Section: Contact Information

First Name : **Tabitha**
Last Name : **Cooney**
Institution : **Dana Farber Cancer Institute**
Address 1 : **450 Brookline Avenue**
Address 2 :
City : **Boston**
State/Province/Region : **MA**
Country : **United States**
Zip/Postal Code : **02215-5450**
Phone Number : **6176324309**
Alternate Phone Number :
Email Address : **tabitha_cooney@dfci.harvard.edu**

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : **Yes**
The specific aims are clear and focused. : **Yes**
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**
Project Title : **Meningiomas in Survivors of Childhood Cancer**
Planned research population (eligibility criteria) :
The study population will consist of all childhood cancer survivors enrolled in both the original and expanded CCSS cohorts. Individuals with unknown treatment exposure will be excluded. Cases of subsequent meningioma will be identified.
Proposed specific aims :
1) To describe the cumulative incidence of meningiomas in survivors of childhood cancer across the original and expanded cohorts. Hypotheses: The incidence of meningioma increases with time from treatment exposure and does not plateau. By treatment era/decade, the incidence of meningioma has decreased due to reduced use of cranial radiation.

2)To describe the patterns of multiple meningiomas among childhood cancer survivors. Hypothesis: More than prior estimates of 10-14% of survivors with meningioma will develop multiple meningioma. Of those with multiple, a portion will be recurrent meningioma.

3) To identify treatment, disease, and sociodemographic characteristics that predict the risk of meningioma.
Hypothesis: Increasing cranial radiation dose, younger age at diagnosis, and female gender will be identified as independent risk factors for meningioma. Intrathecal methotrexate will not be identified.

4) To construct the radiation dose response relationship using first pass radiation exposure data. Hypothesis: A statistically significant radiation dose-response

relationship will be observed for meningioma consistent with prior CCSS reports and reports from other similar cohort studies.

5) To determine all-cause and meningioma-specific mortality among childhood cancer survivors with subsequent meningioma. Hypothesis: Three- and five-year overall survival will be consistent with prior CCSS report, and cause of death will vary and include meningioma, progression of primary cancer, and secondary cancer.

Will the project require non-CCSS funding to complete? : **No**

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : **No**

Biological samples : **No**

Medical record data : **No**

If yes to any of the above, please briefly describe. :

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy : **Primary**

Chronic Disease :

Psychology / Neuropsychology :

Genetics :

Cancer Control : **Secondary**

Epidemiology / Biostatistics :

Section: Outcomes or Correlative Factors

Late mortality : **Secondary**

Second Malignancy : **Primary**

Group: Health Behaviors

Tobacco :

Alcohol :

Physical activity :

Medical screening :

Other :

If other, please specify :

Group: Psychosocial

Insurance :

Marriage :

Education :

Employment :

Other :

If other, please specify :

Group: Medical Conditions

Hearing/Vision/Speech :

Hormonal systems :

Heart and vascular :

Respiratory :
Digestive :
Surgical procedures :
Brain and nervous system :
Other :
If other, please specify :

Group: Medications

Describe medications :

Group: Psychologic/Quality of Life

BSI-18 :
SF-36 :
CCSS-NCQ :
PTS :
PTG :
Other :
If other, please specify :

Group: Other

Pregnancy and offspring :
Family history :
Chronic conditions (CTCAE v3) :
Health status :

Group: Demographic

Age : **Correlative Factors**
Race : **Correlative Factors**
Sex : **Correlative Factors**
Other :
If other, please specify :

Group: Cancer treatment

Chemotherapy : **Correlative Factors**
Radiation therapy : **Correlative Factors**
Surgery : **Correlative Factors**

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center : **Yes**
Local institutional statistician :
If local, please provide the name(s) and contact information of the statistician(s) to be involved. :
Will this project utilize CCSS biologic samples? : **No**
If yes, which of the following? :
If other, please explain :

Section: Other General Comments

Other General Comments :
I agree to share this information with St. Jude : **Yes**